Related Experiment Video
Updated: Sep 19, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
TAMs-specific ARF1 inhibition reprograms glioma microenvironment and enhances the therapeutic effect of oncolytic
Tao Cao1, Tong Hao2, Xiaoru Zhang3
1Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China.
Abstract:
Gliomas, characterized by their robust immunosuppressive microenvironment, pose a significant challenge to the efficacy of immunotherapies. The cGas/STING signaling pathway is emerging as a promising target for cancer immunotherapy. The inhibition of ADP-ribosylation factor 1 (ARF1), a pivotal regulator within cGas/STING signaling pathway, has been shown to enhance the activation cGas/STING. We investigated the impact of macrophage-specific ARF1 suppression on the phenotype of tumor-associated macrophages (TAMs) and the subsequent tumor specific immune response. Our findings reveal that targeted downregulation of ARF1 in TAMs substantially amplifies the immune response induced by oncolytic adenoviruses, effectively reprograms these macrophages, and bolsters anti-tumor immunity. The use of oncolytic adenoviruses armed with ARF1 knockdown elements has been demonstrated to exert a significant suppressive effect on glioma growth through the concerted action of multiple pathways and effectively elicit immune memory, thereby enhancing the survival rates of tumor bearing mice and preventing tumor recurrence.
Insights
Targeting ADP-ribosylation factor 1 (ARF1) in macrophages enhances oncolytic adenovirus immunotherapy for gliomas. Suppressing ARF1 reprograms tumor-associated macrophages, boosting anti-tumor immunity and improving survival rates.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Gliomas present a significant challenge to immunotherapy due to their immunosuppressive microenvironment.
- The cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway is a promising target for cancer immunotherapy.
- ADP-ribosylation factor 1 (ARF1) is a key regulator of the cGAS/STING pathway, and its inhibition can enhance pathway activation.
Purpose of the Study:
- To investigate the effect of macrophage-specific ARF1 suppression on tumor-associated macrophages (TAMs) and the anti-tumor immune response in gliomas.
- To evaluate the efficacy of oncolytic adenoviruses engineered to downregulate ARF1 in TAMs.
Main Methods:
- Utilized oncolytic adenoviruses armed with ARF1 knockdown elements.
- Investigated the phenotypic changes in TAMs following ARF1 suppression.
- Assessed the impact on the tumor-specific immune response and anti-tumor immunity.
Main Results:
- Targeted ARF1 downregulation in TAMs significantly amplified the immune response to oncolytic adenoviruses.
- ARF1 suppression effectively reprogrammed TAMs, enhancing anti-tumor immunity.
- Oncolytic adenoviruses with ARF1 knockdown suppressed glioma growth and elicited immune memory.
Conclusions:
- Macrophage-specific ARF1 suppression is a viable strategy to enhance oncolytic adenovirus immunotherapy for gliomas.
- This approach bolsters anti-tumor immunity, improves survival rates, and prevents tumor recurrence in preclinical models.
